ReviewInflammatory mediators in heart failure
Introduction
It has become more clear over the past decade that many features of the syndrome of chronic heart failure can be explained by the known biological effects of inflammatory mediators. There has been a considerable increase in research in this area and it continues to remain a widely recognised and discussed field. Indeed, when expressed in experimental models at the concentrations that are observed in heart failure, inflammatory mediators such as tumour necrosis factor-α and nitric oxide can produce effects that mimic some clinical features of heart failure, including (but not limited to) progressive left-ventricular dysfunction, pulmonary oedema, left-ventricular remodelling, and cardiomyopathy [1], [2]. Thus, the elaboration of cytokines may be responsible, in part, for disease progression in patients with chronic heart failure [1].
Many cardiologists have learned and many more will need to increase their knowledge about what cytokines are. This is of increasing importance with the advent of anti-cytokine treatment as it has not only been successfully carried out in diseases such as rheumatoid arthritis [3], but for the first time this year in patients with chronic heart failure [4]. It appears that this is just the beginning of a new era of promising therapeutic options.
Section snippets
Inflammatory cytokines
It has become apparent that an ensemble of biologically active molecules termed cytokines, that are different from the better known neurohormons in many ways, are also expressed in the setting of heart failure. The term cytokine refers to a group of protein molecules with relatively small molecular weights (∼15–30 kDa) that are secreted by cells in response to a variety of different inducing stimuli. As opposed to cytokines, polypeptide hormones are generally produced by a specific cell type in
Interleukin-6
Interleukin-6 is a pro-inflammatory cytokine which has been shown to be elevated in patients with chronic heart failure [8], [9], and it is associated with severe symptoms of heart failure as demonstrated by a higher incidence of New York Heart Association (NYHA) functional class III and IV, worse left ventricular function, and a poorer prognosis [2], [10], [11].
In one study it was demonstrated that plasma IL-6 levels not only increased significantly from the femoral artery to the femoral vein
Tumour necrosis factor-α
In 1975, tumour necrosis factor-α (TNF-α) has been discovered in the search for an anti-cancer treatment [14]. While studying ‘haemorrhagic necrosis’ of tumours produced by endotoxin, it was found that the serum of bacillus Calmette–Guerin (BCG)-infected mice treated with endotoxin contained a substance, then termed tumour necrosis factor, which mimicked the tumour necrotic action of endotoxin itself. A variety of tests indicated that TNF was not residual endotoxin, but a factor released from
Cytokines in chronic heart failure
Cytokines have been shown to play a major role in the pathogenesis of various diseases, including chronic heart failure. Elevated levels of the pro-inflammatory cytokine TNF have been documented in patients with chronic heart failure, and this has been found to correlate with the severity of heart failure [18], [19]. Increased expression of tumour necrosis factor (TNF) has been found in cardiac tissue of patients with chronic heart failure undergoing heart transplantation and the failing heart
References (36)
- et al.
Basic mechanisms in heart failure: the cytokine hypothesis
J Card Fail
(1996) - et al.
Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart
Circulation
(1996) - et al.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
N Engl J Med
(1999) - et al.
Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
Circulation
(1999) - et al.
Formation of ion-permeable channels by tumor necrosis factor-alpha
Science
(1992) - et al.
The role of cytokines in disease progression in heart failure
Curr Opin Cardiol
(1997) - et al.
Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation
J Am Coll Cardiol
(1998) - et al.
Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Am J Cardiol
(1996) - et al.
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Am J Cardiol
(1999) - et al.
Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy
Am J Cardiol
(1998)
Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
J Am Coll Cardiol
Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex
J Biol Chem
Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes
Circulation
An endotoxin-induced serum factor that causes necrosis of tumors
Proc Natl Acad Sci USA
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells
J Exp Med
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
Nature
Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
Circulation
Wasting as independent risk factor for mortality in chronic heart failure
Lancet
Cited by (29)
Reversing heart failure-associated pathophysiology with exercise: What actually improves and by how much?
2015, Heart Failure ClinicsCitation Excerpt :Based on these observations, the muscle hypothesis of HF was born: that alterations in the peripheral skeletal muscle are a main predictor for exercise intolerance and that these alterations are influenced by ET.96,97 During the development of HF, a derangement in inflammatory factors is evident.98,99 The prototype of inflammatory cytokines elevated in HF is tumor necrosis factor α (TNF-α).100,101
Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients
2008, Experimental and Molecular PathologyHeart failure as a cause for hospitalization in chronic dialysis patients
2003, American Journal of Kidney DiseasesCitation Excerpt :HF also is more common than ischemic heart disease after renal transplantation12,17,18 and in patients with diabetes on the renal transplant waiting list.3,19 The 83% mortality rate post-HF development at 3 years in this cohort is similar to the 89% mortality rate described after acute myocardial infarction by Herzog et al20 and the 80% mortality rate after acute myocardial infarction reported from the same DMMS Wave 2 database,16 which has notable similarities to Rigatto et al.17 These observations support the concept that hospitalization for HF is more common and just as lethal as ischemic heart disease in chronic dialysis patients, consistent with a previous multicenter study of chronic dialysis patients,1 findings in nonuremic patients with HF,21,22 and after renal transplantation.12,17,18 The present study confirms that many risk factors for HF in other populations also are risk factors for HF in dialysis patients (Table 5).2,3,17,23
The metabolic extension of research in cardiology into the better understanding of cachexia: Role of the International Journal of Cardiology
2002, International Journal of Cardiology